QURE Stock Analysis: Uniqure | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.780m USD | 12M Return: 213.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 57.5M
Qual. Beats: -1
Rev. Trend: -56.4%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
uniQure N.V. (NASDAQ: QURE) is a Netherlands-based biotechnology company headquartered in Amsterdam that develops gene therapies for patients with rare and other serious diseases. Founded in 1998, it operates in the U.S. market and is classified within the Health Care sectors Biotechnology sub-industry. As a gene therapy developer, uniQure uses adeno-associated virus (AAV)-based vectors to deliver functional genes into patient cells, a modality aimed at addressing conditions with limited or no existing treatment options.
The companys sole commercial product is HEMGENIX, a gene therapy approved for adults with hemophilia B, allowing them to produce their own factor IX and reduce bleeding risk. Its pipeline is centered on AMT-130, an AAV-based gene therapy in Phase I/II development for Huntingtons disease, alongside earlier-stage candidates AMT-260 for mesial temporal lobe epilepsy, AMT-162 for SOD1-related ALS, and AMT-191 for Fabry disease. The companys focus on rare and orphan diseases typically positions it to benefit from regulatory pathways such as FDA Orphan Drug designation, which can provide extended market exclusivity periods.
uniQure pursues its pipeline through a mix of internal development and external partnerships, including a licensing agreement with Apic Bio for an SOD1-ALS gene therapy and a development and commercial supply agreement with CLS Behring. The company went public on NASDAQ in 2007 and currently carries a mid-cap valuation, reflecting investor expectations tied primarily to the commercial uptake of HEMGENIX and the clinical progress of its Huntingtons disease program.
- AMT-130 Huntingtons disease trial data drives stock volatility
- HEMGENIX commercial uptake in hemophilia B market accelerates
- Cash burn raises dilution risk amid advancing gene therapy pipeline
| Net Income: -252.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.22 > 0.02 and ΔFCF/TA 8.77 > 1.0 |
| NWC/Revenue: 4.02k% < 20% (prev 2.56k%; Δ 1.46k% < -1%) |
| CFO/TA -0.16 > 3% & CFO -160.8m > Net Income -252.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.01 > 1.5 & < 3 |
| Outstanding Shares: last quarter (66.2m) vs 12m ago 20.87% < -2% |
| Gross Margin: 76.59% > 18% (prev 82.61%; Δ -6.03% > 0.5%) |
| Asset Turnover: 2.38% > 50% (prev 2.45%; Δ -0.07% > 0%) |
| Interest Coverage Ratio: -2.98 > 6 (EBIT TTM -177.7m / Interest Expense TTM 59.7m) |
| A: 0.76 (Total Current Assets 834.3m - Total Current Liabilities 83.3m) / Total Assets 985.1m |
| B: -1.49 (Retained Earnings -1.46b / Total Assets 985.1m) |
| C: -0.23 (EBIT TTM -177.7m / Avg Total Assets 785.0m) |
| D: 0.49 (Book Value of Equity 324.1m / Total Liabilities 661.1m) |
| Altman-Z'' = -0.85 = CCC |
| DSRI: 1.87 (Receivables 13.7m/5.61m, Revenue 18.7m/14.3m) |
| GMI: 1.08 (GM 82.61% / 76.59%) |
| AQI: 0.52 (AQ_t 0.13 / AQ_t-1 0.25) |
| SGI: 1.30 (Revenue 18.7m / 14.3m) |
| TATA: -0.09 (NI -252.2m - CFO -160.8m) / TA 985.1m) |
| Beneish M = -2.31 (Cap -4..+1) = BBB |
As of August 01, 2026, the stock is trading at USD 43.63 with a total of 1,694,976 shares traded. Over the past week, the price has changed by +11.96%, over one month by -5.28%, over three months by +118.70% and over the past year by +213.43%.
Current recommended Stop Loss: 40.90 (which is 6.3% or 1 ATR below the current price).
Uniqure has received a consensus analysts rating of 4.54. Therefore, it is recommended to buy QURE.
- StrongBuy: 9
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 65.3 | 49.6% |
P/E Forward = 27.933
P/S = 153.6236
P/B = 16.9097
Revenue TTM = 18.7m USD
EBIT TTM = -177.7m USD
EBITDA TTM = -163.3m USD
Long Term Debt = 49.7m USD (from longTermDebt, last fiscal year)
Short Term Debt = 5.98m USD (from shortTermDebt, last quarter)
Debt = 76.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 13.4m
Net Debt = -310.7m USD (calculated: Debt 76.2m - CCE 386.9m)
Enterprise Value = 2.47b USD (2.78b + Debt 76.2m - CCE 386.9m)
Interest Coverage Ratio = -2.98 (Ebit TTM -177.7m / Interest Expense TTM 59.7m)
EV/FCF = -11.20x (Enterprise Value 2.47b / FCF TTM -220.5m)
FCF Yield = -8.93% (FCF TTM -220.5m / Enterprise Value 2.47b)
FCF Margin = -1.18k% (FCF TTM -220.5m / Revenue TTM 18.7m)
Net Margin = -1.35k% (Net Income TTM -252.2m / Revenue TTM 18.7m)
Gross Margin = 76.59% ((Revenue TTM 18.7m - Cost of Revenue TTM 4.37m) / Revenue TTM)
Gross Margin QoQ = 94.01% (prev 93.85%)
Tobins Q-Ratio = 2.51 (Enterprise Value 2.47b / Total Assets 985.1m)
Interest Expense / Debt = 78.32% (Interest Expense 59.7m / Debt 76.2m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -140.4m (EBIT -177.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 9.45 (Total Current Assets 834.3m / Total Current Liabilities 88.3m)
Debt / Equity = 0.24 (Debt 76.2m / totalStockholderEquity, last quarter 324.1m)
Debt / EBITDA = 1.90 (negative EBITDA) (Net Debt -310.7m / EBITDA -163.3m)
Debt / FCF = 1.41 (negative FCF - burning cash) (Net Debt -310.7m / FCF TTM -220.5m)
Total Stockholder Equity = 225.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -32.13% (Net Income -252.2m / Total Assets 985.1m)
RoE = -112.0% (Net Income TTM -252.2m / Total Stockholder Equity 225.3m)
RoCE = -64.64% (EBIT -177.7m / Capital Employed (Equity 225.3m + L.T.Debt 49.7m))
RoIC = -15.48% (negative operating profit) (NOPAT -140.4m / Invested Capital 906.8m)
WACC = 13.77% (E(2.78b)/V(2.86b) * Re(14.15%) + (debt cost/tax rate unavailable))
Discount Rate = 14.15% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 95.67 | Cagr: 14.98%
[DCF] Fair Price = unknown (Cash Flow -220.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.95 | # QB: -1
Revenue Correlation: -56.38 | Revenue CAGR: -29.36% | SUE: 0.24 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.74 | Chg30d=+10.40% | Revisions=-50% | Analysts=7
EPS current Year (2026-12-31): EPS=-3.09 | Chg30d=+3.15% | Revisions=-50% | GrowthEPS=-5.4% | GrowthRev=+38.9%
EPS next Year (2027-12-31): EPS=-2.47 | Chg30d=+4.13% | Revisions=+10% | GrowthEPS=+20.1% | GrowthRev=+482.2%
[Analyst] Revisions Ratio: -38% (up=6, down=15)